RBC Capital Maintains Outperform on Aptose Biosciences, Lowers Price Target to $23
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on Aptose Biosciences (NASDAQ:APTO) but lowered the price target from $40 to $23.
August 11, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained an 'Outperform' rating on Aptose Biosciences but lowered the price target from $40 to $23.
The news is directly about Aptose Biosciences. While the 'Outperform' rating is maintained, the lowering of the price target could create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100